Bioxytran Reports Q2 2025 Net Profit of $35,437 Amid Ongoing Financial Challenges

Bioxytran, Inc. has reported its financial results for the second quarter and first half of 2025, revealing a net profit of $35,437 for the three months ending June 30, 2025, a significant improvement compared to a net loss of $661,647 during the same period in 2024. However, for the six months ended June 30, 2025, the company recorded a net loss of $1,318,197, slightly higher than the loss of $1,222,169 reported in the prior year. The company has not yet generated any revenue, and its accumulated deficit has increased to $20,239,366 from $18,921,169 at the end of 2024.

The financial performance reflects a notable reduction in operating expenses, which totaled $739,220 for the first half of 2025, down from $1,388,551 in the same period of 2024. This decrease was primarily driven by a significant reduction in general and administrative expenses, which fell to $253,300 from $778,872 year-over-year. Research and development expenses also increased to $452,000 in the first half of 2025, compared to just $27,000 in the previous year, indicating a strategic focus on advancing its product pipeline.

In terms of operational developments, Bioxytran has made significant strides in its clinical research activities. The company is currently focused on developing therapeutic molecules for stroke, with its lead product, BXT-25, designed to treat ischemic strokes. The company has also received approval for several clinical trials, including a Phase 1b/2a study for ProLectin-M, which is expected to commence in the third quarter of 2025. Additionally, Bioxytran has expanded its organizational structure by acquiring minority interests in its subsidiaries, Pharmalectin, Inc. and NDPD Pharma, Inc., enhancing its operational capabilities.

Despite these advancements, the company faces substantial financial challenges, with total liabilities reaching $2,782,771 as of June 30, 2025, up from $1,930,642 at the end of 2024. The increase in liabilities is attributed to higher accounts payable and accrued expenses, as well as a derivative liability of $684,002 related to its convertible notes. The company reported a negative working capital of $2,779,627, raising concerns about its ability to continue operations without additional funding. Bioxytran is actively seeking to raise at least $3,700,000 to support its operations over the next 15 months, but there is no assurance that it will be able to secure the necessary financing.

Looking ahead, Bioxytran's management has indicated that the future of the company is contingent upon its ability to obtain sufficient funding to support its drug development activities and regulatory submissions. The company plans to pursue private placements and public offerings to raise capital, but it acknowledges the risks associated with its current financial position and the potential need to scale back operations if funding is not secured.